BIOCRYST PHARMACEUTICALS, INC. (BCRX) Net margin 2016–2025
BIOCRYST PHARMACEUTICALS, INC. (BCRX) net profit margin by fiscal year — reported net income divided by reported revenue.
30.2%FY2025 · since FY2016: -209.3% → 30.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 30.2% | +49.9 pp |
| FY2024 | -19.7% | +48.6 pp |
| FY2023 | -68.4% | +22.9 pp |
| FY2022 | -91.2% | +25.9 pp |
| FY2021 | -117.1% | +909.2 pp |
| FY2020 | -1026.4% | -803.4 pp |
| FY2019 | -223.0% | +267.3 pp |
| FY2018 | -490.3% | -229.1 pp |
| FY2017 | -261.2% | -51.9 pp |
| FY2016 | -209.3% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More BCRX financial trends
BCRX RevenueBCRX Net incomeBCRX Gross profitBCRX Gross marginBCRX Operating incomeBCRX Operating marginBCRX Operating cash flowBCRX Free cash flowBCRX Capital expendituresBCRX Return on equityBCRX Stock buybacksBCRX Dividends paidBCRX Total assetsBCRX Total liabilitiesBCRX Shareholders’ equityBCRX overview →